Navigation Links
Clinical guide on selective estrogen receptor modulators for postmenopausal osteoporosis
Date:2/28/2012

Amsterdam, February 28, 2012 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of an important clinical guide from the European Menopause and Andropause Society (EMAS) in the February issue of Maturitas. This clinical guide details the role of selective estrogen receptor modulators (SERMs) against postmenopausal osteoporosis as the European Medicines Agency (EMA) has approved the use of bazedoxifene and lasofoxifene.

Postmenopausal osteoporosis and resulting fractures have a major impact on morbidity and mortality and are major public health issues. Various therapies such as bisphosphonates, strontium ranelate and more recently denomsumab are available but these are not suitable for all women. Health concerns have been raised resulting from these therapies, such as oesophageal cancer, osteonecrosis of the jaw (ONJ) and subtrochanteric fractures with bisphosphonates and venous thromboembolism with strontiumranelate. Use of bazedoxifene and lasofoxifene will increase the number of therapeutic options available as these new SERMs point to a greater anti-fracture potential.

The decision of which type of treatment to use for osteoporosis and when to begin should be based on the need to reduce fracture risk. All treatments including SERMs should include recommendations for a healthy life style and adequate calcium and vitamin D intake. Additional benefits of different agents (i.e. climacteric symptom improvement with estrogens, breast cancer prevention for SERMS) must be considered when selecting the anti-osteoporosis drug. Furthermore what agent is used (estrogen, SERM, bisphosphonates) may vary over a woman's life time. The clinical guide from the European Menopause and Andropause Society (EMAS) details all important and necessary aspects of consideration.


'/>"/>

Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Source:Eurekalert

Page: 1

Related biology news :

1. First vaccine against fatal visceral leishmaniasis enters clinical trial
2. Using online patient communities and new trial approaches to optimize clinical research
3. EASL publishes first European Clinical Practice Guidelines for Wilsons disease
4. Verified Clinical Trials System Implemented at Leading Global Contract Research Organization to Improve Participant Safety and Data Integity
5. Ambry Genetics Reports Results from Clinical Diagnostic Exomeâ„¢ Testing of Three Patients
6. HIV/AIDS vaccine developed at Western proceeding to human clinical trials
7. Identify clinically relevant fungi confidently and accurately
8. Global resource for clinical microbiologists and immunologists debuts
9. Commentary and podcast on landmark gene therapy clinical trial for hemophilia B
10. BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS
11. Seena clinical trials named for pancreatic cancer advocate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  Bioethics International, a not-for-profit organization focused ... developed, marketed and made accessible to patients around the world, ... had named the publication of the Good Pharma Scorecard ... is also featured as one of BMJ Open ,s ... year that are most frequently read. Ed Sucksmith ...
(Date:2/11/2016)... 11, 2016 --> ... "Company") (OTCQB: PSID), a life sciences company focused ... Thermomedics subsidiary, which markets the Caregiver® FDA-cleared non-contact ... in January 2016, including entering into agreements with ... sales growth, and establishing several near-term pipeline opportunities. ...
(Date:2/10/2016)... - BioAmber Inc. (NYSE: BIOA ), a leader ... & Co. Ltd., its partner in the ... an additional CDN$25 million in the joint venture for ... to 40%.  Mitsui will also play a stronger role ... Sarnia , providing dedicated resources alongside BioAmber,s ...
(Date:2/10/2016)... York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has ... develop new vaccines and immunotherapies for infectious diseases and cancer. , ...
Breaking Biology Technology: